Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Clinical trial NCT02638103 · COMPLETED
Trial details
- NCT number
- NCT02638103
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-26
- Primary completion
- 2018-06-06
- Enrollment
- 1890
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.